Vascular and Endovascular Surgery Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Vascular and Endovascular Surgery Department, Faculty of Medicine, Cairo University, Cairo, Egypt; Vascular and Endovascular Surgery Department, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.
J Vasc Surg Venous Lymphat Disord. 2024 Jan;12(1):101692. doi: 10.1016/j.jvsv.2023.09.006. Epub 2023 Oct 4.
Patients on hemodialysis are particularly vulnerable to central venous occlusion (CVO). Endovascular treatment has gained wide acceptance for the treatment of CVO. However, difficulties in crossing the occluded segment can be encountered during conventional endovascular management. Sharp recanalization has been adopted when conventional endovascular methods could not recanalize the obstructed region. This study aimed to assess the outcome of the sharp venous recanalization technique with angioplasty and stenting in the treatment of CVO in Egyptian patients undergoing hemodialysis.
This retrospective study is based on data from a prospectively maintained department database of patients under regular hemodialysis who underwent the sharp venous recanalization technique for CVO. Routinely, the patients were followed up at 3, 6, and 12 months with a clinical examination. The primary outcomes were technical success and primary patency. Secondary outcomes included complication rates and clinical success.
This study included 40 patients. Thirty-six patients (90%) achieved technical and clinical success. Seven patients (17.5%) had immediate postoperative complications. Four cases had minor complications (10%) and three patients had major complications (7.5%): hemothorax in two patients (5.1%) and pneumothorax in one patient (2.6%). At the 1-year follow-up, reintervention was required in nine patients (22.5%), with primary patency rate of 77.5% and a secondary patency rate of 100%.
Sharp recanalization offers a solution for patients undergoing hemodialysis who developed CVO and failed to be recanalized using the conventional endovascular method. It offered promising technical success, clinical improvement, and good primary patency rates.
血液透析患者特别容易发生中心静脉闭塞(CVO)。血管内治疗已广泛应用于 CVO 的治疗。然而,在常规血管内管理中,可能会遇到穿过闭塞段的困难。当常规血管内方法无法使阻塞区域再通时,采用了尖锐再通。本研究旨在评估在埃及血液透析患者中,采用血管成形术和支架置入治疗 CVO 的尖锐静脉再通技术的疗效。
本回顾性研究基于定期接受血液透析且接受尖锐静脉再通技术治疗 CVO 的患者的前瞻性维护部门数据库中的数据。通常,患者在 3、6 和 12 个月时进行临床检查以进行随访。主要结局为技术成功率和初始通畅率。次要结局包括并发症发生率和临床成功率。
本研究纳入了 40 例患者。36 例患者(90%)达到了技术和临床成功。7 例患者(17.5%)术后立即发生并发症。4 例为轻微并发症(10%),3 例为严重并发症(7.5%):2 例患者(5.1%)为血胸,1 例患者(2.6%)为气胸。在 1 年随访时,9 例患者(22.5%)需要再次介入治疗,初始通畅率为 77.5%,次级通畅率为 100%。
尖锐再通为血液透析患者提供了一种解决方案,这些患者发生了 CVO,且无法通过常规血管内方法再通。它提供了有希望的技术成功率、临床改善和良好的初始通畅率。